Table 3. Association between CHRNA7 SNPs, haplotypes, and ChEI response by gender.
| Dominant model | ||||||
| Haplotype | SNP/ | |||||
| block | Haplotype | 0 copies | 1 or 2 copies | |||
| (frequency among | Responder/ | AOR | Responder/ | AOR (95% CI) | P interaction | |
| all ChEI users) | Non-responder | Non-responder | ||||
| 1 | SNP1 All | 19/43 | 1.00 | 42/100 | 1.08 (0.55–2.15) | 0.43 |
| F | 10/29 | 1.00 | 27/64 | 1.32 (0.53–3.27) | ||
| M | 9/14 | 1.00 | 15/36 | 0.76 (0.26–2.24) | ||
| 1 | SNP2 All | 38/106 | 1.00 | 21/33 | 1.70 (0.85–3.39) | 0.01 |
| F | 19/74 | 1.00 | 16/18 | 3.62 (1.47–8.89)* | ||
| M | 19/32 | 1.00 | 5/15 | 0.55 (0.16–1.82) | ||
| 2 | SNP3 All | 23/51 | 1.00 | 38/90 | 0.92 (0.48–1.77) | 0.29 |
| F | 11/31 | 1.00 | 26/62 | 1.22 (0.51–2.94) | ||
| M | 12/20 | 1.00 | 12/28 | 0.62 (0.22–1.74) | ||
| 3 | SNP4 All | 18/44 | 1.00 | 43/98 | 1.14 (0.57–2.26) | 0.62 |
| F | 10/27 | 1.00 | 27/66 | 1.28 (0.51–3.21) | ||
| M | 8/17 | 1.00 | 16/32 | 1.02 (0.34–3.01) | ||
| 3 | SNP5 All | 28/66 | 1.00 | 31/75 | 1.08 (0.56–2.07) | 0.45 |
| F | 17/41 | 1.00 | 18/52 | 0.91 (0.39–2.15) | ||
| M | 11/25 | 1.00 | 13/23 | 1.41 (0.51–3.93) | ||
| 3 | SNP6 All | 26/62 | 1.00 | 35/80 | 1.04 (0.54–1.99) | 0.62 |
| F | 15/39 | 1.00 | 22/54 | 1.15 (0.49–2.68) | ||
| M | 11/23 | 1.00 | 13/26 | 0.98 (0.33–2.85) | ||
| 3 | SNP7 All | 22/48 | 1.00 | 39/94 | 0.97 (0.50–1.88) | 0.15 |
| F | 15/27 | 1.00 | 22/66 | 0.68 (0.29–1.61) | ||
| M | 7/21 | 1.00 | 17/28 | 1.85 (0.62–5.51) | ||
| 4 | SNP8 All | 53/124 | 1.00 | 6/18 | 0.83 (0.30–2.30) | 0.85 |
| F | 30/79 | 1.00 | 5/14 | 0.84 (0.26–2.69) | ||
| M | 23/45 | 1.00 | 1/4 | 0.69 (0.07–6.92) | ||
| 4 | SNP9 All | 33/83 | 1.00 | 28/59 | 1.38 (0.72–2.63) | 0.85 |
| F | 18/51 | 1.00 | 19/42 | 1.42 (0.62–3.26) | ||
| M | 15/32 | 1.00 | 9/17 | 1.22 (0.42–3.54) | ||
| 1 | Hap1: TC All | 16/30 | 1.00 | 45/113 | 0.91 (0.44–1.90) | 0.30 |
| (54%) F | 10/16 | 1.00 | 27/77 | 0.68 (0.26–1.77) | ||
| M | 6/14 | 1.00 | 18/36 | 1.46 (0.45–4.78) | ||
| 1 | Hap2: GC All | 33/64 | 1.00 | 28/79 | 0.72 (0.38–1.36) | 0.46 |
| (31%) F | 21/41 | 1.00 | 16/52 | 0.56 (0.25–1.29) | ||
| M | 12/23 | 1.00 | 12/27 | 0.95 (0.34–2.64) | ||
| 1 | Hap3: GG All | 40/110 | 1.00 | 21/33 | 1.67 (0.84–3.30) | 0.01 |
| (15%) F | 21/75 | 1.00 | 16/18 | 3.34 (1.38–8.06)* | ||
| M | 19/35 | 1.00 | 5/15 | 0.54 (0.16–1.79) | ||
Abbreviations: SNP, single nucleotide polymorphism; ChEI, cholinesterase inhibitor;
M, male; F, female; AOR, adjusted odds ratio; CI, confidence interval.
All models were adjusted for age, baseline MMSE, hypertension, and APOE ε4 status.
The association remained significant after correction for multiple tests by false discovery rate (FDR) among AD women.